<p>Targeted Prodrug-Based Self-Assembled Nanoparticles for Cancer Therapy</p>

Abstract

Background: Targeted prodrug has various applications as drug formulation for tumor therapy. Therefore, amphoteric small-molecule prodrug combined with nanoscale characteristics for the self-assembly of the nano-drug delivery system (DDS) is a highly interesting research topic. Methods and Results: In this study, we developed a prodrug self-assembled nanoplatform, 2-glucosamine-fluorescein-5(6)-isothiocyanate-glutamic acid-paclitaxel (2DA-FITC-PTX NPs) by integration of targeted small molecule and nano-DDS with regular structure and perfect targeting ability. 2-glucosamine (DA) and paclitaxel were conjugated as the targeted ligand and anti-tumor chemotherapy drug by amino acid group. 2-DA molecular structure can enhance the targeting ability of prodrug-based 2DA-FITC-PTX NPs and prolong retention time, thereby reducing the toxicity of normal cell/tissue. The fluorescent dye FITC or near-infrared fluorescent dye ICG in prodrug-based DDS was attractive for in vivo optical imaging to study the behavior of 2DA-FITC-PTX NPs. In vitro and in vivo results proved that 2DA-FITC-PTX NPs exhibited excellent targeting ability, anticancer activity, and weak side effects. Conclusion: This work demonstrates a new combination of nanomaterials for chemotherapy and may promote prodrug-based DDS clinical applications in the future.

Amentoflavone-loaded nanoparticles enhanced chemotherapy efficacy by inhibition of AKR1B10

“…The control group was replaced with 200 μl of PBS. The experimental method was consistent with that described by Wang et al [44]. The serum biochemical parameters, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatine kinase (CK), and creatine kinase-MB (CK-MB), were detected at preset time points.…”

Extracellular‐Vesicle‐Based Drug Delivery Systems for Enhanced Antitumor Therapies through Modulating the Cancer‐Immunity Cycle

“…[ 35,36 ] As footstone of cancer‐immunity cycle, sufficient tumor antigens provide more opportunities for efficient antigen presentation and T cell activation. Deficient cytotoxicity against tumor cells due to weak tumor targeting ability of drug delivery systems, [ 37,38 ] and single treatment strategy, etc., [ 39 ] is the core factor inducing less tumor antigen release. Second, restricted antigen presentation impairs T cell activation.…”

Fabrication of a composite 3D-printed titanium alloy combined with controlled in situ drug release to prevent osteosarcoma recurrence

“…Based on this advantage, many advanced environmentally responsive NPs have been designed and developed, such as polymeric NPs, micelles, vesicles, nanogels, and liposomes [ [20] , [21] , [22] ]. Among them, prodrug-based NPs have received much attention owing to their simple structure and potential in clinical translation [ [23] , [24] , [25] ]. In the case of many malignant tumors, an acidic environment is present locally in the microenvironment because of glycolysis and lactic acid accumulation in the tumor [ 26 , 27 ].…”